糖尿病性黄斑水肿研究进展

洪江 刘(承德医学院附属医院，中国)
志军 董(承德医学院附属医院，中国)

摘要

糖尿病性黄斑水肿（Diabetic Macular Edema，DME）是一种常见的眼科疾病，它是由于糖尿病引起的视网膜血管病变（Diabetic Retinopathy，DR）导致的视网膜中央部位的水肿。DME会影响患者的中心视力，严重者甚至可能导致失明。因此，及时诊断和治疗DME是非常重要的。DME的发病机制涉及多种因素，包括血—视网膜屏障的破坏、炎症反应和神经退行性改变。治疗方法包括药物治疗、激光治疗和手术治疗。DME的预后评估对于指导治疗和了解病情的发展也非常重要。论文综述了DME的研究进展，包括其发病机制、治疗方法和预后评估，旨在为临床实践和科学研究提供参考。

关键词

糖尿病性黄斑水肿；发病机制；治疗策略；预后评估

参考

Lundeen EA, Andes LJ, Rein DB, et al. Trends in Prevalence and Treatment of Diabetic Macular Edema and Vision-Threatening Diabetic Retinopathy Among Medicare Part B Fee-for-Service Beneficiaries[J]. JAMA Ophthalmol, 2022,140(4):345-353.

Soni P, Singh AK, Marndi SJ. Study of efficacy of intravitreal triamcinolone acetonide (IVTA) for the treatment of refractory diabetic macular edema (DME) in type 2 diabetes mellitus patients[J].Indian J Clin Exp Ophthalmol,2019,5(3):401-406.

Simó R, Hernández C. Advances in the Medical Treatment of Diabetic Retinopathy[J].Diabetes Care,2009,32(8):1556-1562.

Chauhan MZ, Rather PA, Samarah SM, et al. Current and Novel Therapeutic Approaches for Treatment of Diabetic Macular Edema[J].Cells,2022,11(12):1950.

Li J, Xie R, Jiang F, et al. Tumor necrosis factor ligand-related molecule 1A maintains blood–retinal barrier via modulating SHP-1-Src-VE-cadherin signaling in diabetic retinopathy[J].FASEB,2021(35):22008.

Kyryliuk M, Suk S. Pathogenesis of diabetic macular edema: the role of pro-inflammatory and vascular factors. A literature review[J].International Journal of Endocrinology,2022,18(3):180-183.

Sharma S, Nagrale P. Automated quantification of macular edema in patients with diabetic macular edema and their response to anti-VEGF: A study protocol [version 1; peer review: awaiting peer review]. F1000Research,2023(12):1453.

Tangvarasittichai O, Tangvarasittichai S. Oxidative Stress, Ocular Disease and Diabetes Retinopathy[J].Current Pharmaceutical Design,2018,24(40).

李诗燚,王柯,邹文军.线粒体自噬参与糖尿病视网膜病变的研究进展[J].国际眼科杂志,2023,23(8):1312-1316.

Sharma D, Zachary I, Jia H. Mechanisms of Acquired Resistance to Anti-VEGF Therapy for Neovascular Eye Diseases[J].Ophthalmol,2023,64(5):28.

Alsaedi NG, Alselaimy RM, Alshamrani AA, et al. Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema[J].Clin Ophthalmol,2021(15):2975-2980.

Tsiropoulos GN, Seliniotaki AK, Haidich AB, et al. Comparison of adverse events between intravitreal anti-VEGF and laser photocoagulation for treatment-requiring retinopathy of prematurity: a systematic review[J].Int Ophthalmol,2023(43):1027-1062.

杭帆,谭薇,黄智华.577nm阈值下微脉冲激光与传统激光治疗DME疗效的系统评价[J].国际眼科杂志,2020,20(6):1011-1015.

Abd Elhamid AH. Quantitative Assessment of Outer Retinal Layer and Photoreceptor Outer Segment Layer and Their Relation to Visual Acuity in Diabetic Macular Edema[J].Journal of Ophthalmology,2019(7):8216150.

中华医学会眼科学分会眼底病学组,中国医师协会眼科医师分会眼底病学组.我国糖尿病视网膜病变临床诊疗指南(2022年)[J].中华眼底病杂志,2023,39(2):99-124.

Marolo P, Borrelli E, Gelormini F, et al. Retinal Thickness Deviation: A New OCT Parameter for Assessing Diabetic Macular Edema[J].Clin Med,2023(12):3976.

Zhang CH, Gong B, Huang C, et al. Morphological and functional changes in the macular area in diabetic macular edema after a single intravitreal injection of aflibercept[J].Ophthalmol,2023,16(1):88-94.

Hohberger B, Ganslmayer M, Lucio M, et al. Retinal Microcirculation as a Correlate of a Systemic Capillary Impairment After Severe Acute Respiratory Syndrome Coronavirus 2 Infection[J].Med,2021(8):676554.

DOI: http://dx.doi.org/10.12345/yzlcyxzz.v7i3.16256